Neutralizer A Contact Plates from Merck Millipore Improve Detection of Microorganisms in Isolators and Cleanrooms
Merck Millipore's heipha ICRplus Neutralizer A contact plates improve detection of micro-organisms on disinfected surfaces in isolators and cleanrooms. Common disinfectants may contain residues from a variety of sources that inhibit the detection of microorganisms during surface monitoring, which can lead to false negative results.
Heipha Neutralizer A ICRplus contact plates allow the detection of micro-organisms in the presence of many disinfectants, including those which cannot be sufficiently inactivated by common neutralizers, such as polysorbate 80, lecithin, histidine and thiosulfate. The medium in the plates is supplemented with a mixture of ingredients called Neutralizer A to inactivate residues of a broad range of disinfectants including polyhexamethylene biguanides and quaternary ammonium compounds. The basic medium complies with the formulation of casein soya bean digest agar according to the recommendation of the current European, Japanese and United States Pharmacopoeia.
Heipha Neutralizer A ICRplus contact plates are triple-bagged, gamma-irradiated and the only plates available that feature a two-way closure system. The closed position ensures safe transport after sampling and is suitable for aerobic incubation while the vent position provides the required gas exchange for the detection of anaerobic and microaerophilic microorganisms in specific incubation atmospheres. In addition, the clear appearance of the agar medium makes analysis easier.
The plates can be stored at room temperature and have a long shelf life of 6 months. Each heipha Neutralizer A ICRplus contact plate contains a data matrix barcode, which allows secure identification of plates and supports the "paperless" lab.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.